Addex Therapeutics Ltd (ADDXF)
| Previous Close | 1.5600 |
| Open | 1.5600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.5600 - 1.5600 |
| 52 Week Range | 1.5600 - 1.6500 |
| Volume | 5,000 |
| Avg. Volume | 0 |
| Market Cap | 50.58M |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Addex to Present at the Virtual German Equity Forum
Geneva, Switzerland, November 18, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Head of Discovery – Biology, Dr Robert Lütjens, will be attending the virtual German Equity Forum to be held November 22 – 24, 2021. Mr Dyer’s presentation is scheduled for November 23, 2021 at 08:00 EST / 14:00 CET. In his presentation, Mr Dyer will provide a c
- GlobeNewswire
Addex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
Geneva, Switzerland, November 15, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 7th Annual Israel Virtual Conference. In his presentation, which is scheduled for today, November 15, 2021 at 08:30 EST / 14:30 CET, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video prese
- GlobeNewswire
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
Setting Up Global Expansion of Phase 2 Clinical Evaluation in Epilepsy Patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has successfully completed Phase 1 studies in Japan with
